A Case Report of Diabetic Ketoacidosis Associated with Multiple Risk Factors Including Dapagliflozin Use

Sodium-glucose linked transporter 2 (SGLT2) inhibitors are a new class of antihyperglycemic agents that inhibit renal glucose reabsorption. This group of medications got more popular in diabetic management as it help to control the blood sugar level and it induce weight loss. However, FDA issued a warning of possible association between SGLT2 inhibitors usage and DKA after the reports of several euglycemic DKA cases associated with the use of SGLT2 inhibitors.